• +1-646-491-9876
    • +91-20-67278686

    Search

    Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2017

    Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2017

    • Report Code ID: RW0001689409
    • Category Healthcare
    • No. of Pages 40
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2017, provides an overview of the Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline landscape.

    Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called functional dyspepsia or non-ulcer stomach pain. Signs and symptoms include burning sensation or discomfort in your upper abdomen or lower chest, sometimes relieved by food or antacids, bloating, belching and nausea. The predisposing factors include consuming excessive amounts of caffeine or alcohol, smoking and taking certain medications, especially certain over-the-counter pain relievers, such as aspirin and ibuprofen (advil, motrin, others), which can cause stomach problems. Treatment includes medications to reduce acid production, antibiotics and low-dose antidepressants.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

    Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Functional (Non Ulcer) Dyspepsia (Gastrointestinal).
    - The pipeline guide reviews pipeline therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Functional (Non Ulcer) Dyspepsia (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Functional (Non Ulcer) Dyspepsia (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Functional (Non Ulcer) Dyspepsia - Overview
    Functional (Non Ulcer) Dyspepsia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Functional (Non Ulcer) Dyspepsia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Functional (Non Ulcer) Dyspepsia - Companies Involved in Therapeutics Development
    Abide Therapeutics Inc
    Daewoong Pharmaceutical Co Ltd
    RaQualia Pharma Inc
    Yuhan Corp
    Zensun (Shanghai) Sci & Tech Co Ltd
    Zeria Pharmaceutical Co Ltd
    Functional (Non Ulcer) Dyspepsia - Drug Profiles
    5-BIOP - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ABX-1431 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    acotiamide hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LT-4005 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mosapride SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naronapride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RQ-00000010 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RQ-00201894 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YH-12852 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZS-07 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Functional (Non Ulcer) Dyspepsia - Dormant Projects
    Functional (Non Ulcer) Dyspepsia - Discontinued Products
    Functional (Non Ulcer) Dyspepsia - Product Development Milestones
    Featured News & Press Releases
    Dec 14, 2016: Abide Therapeutics Announces First Patient Dosed in Phase 1b Study to Assess the Effect of ABX-1431 in Patients with Functional Dyspepsia
    Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia
    Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Functional (Non Ulcer) Dyspepsia - Pipeline by Abide Therapeutics Inc, H1 2017
    Functional (Non Ulcer) Dyspepsia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Functional (Non Ulcer) Dyspepsia - Pipeline by RaQualia Pharma Inc, H1 2017
    Functional (Non Ulcer) Dyspepsia - Pipeline by Yuhan Corp, H1 2017
    Functional (Non Ulcer) Dyspepsia - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017
    Functional (Non Ulcer) Dyspepsia - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2017
    Functional (Non Ulcer) Dyspepsia - Dormant Projects, H1 2017
    Functional (Non Ulcer) Dyspepsia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Abide Therapeutics Inc
    Daewoong Pharmaceutical Co Ltd
    RaQualia Pharma Inc
    Yuhan Corp
    Zensun (Shanghai) Sci & Tech Co Ltd
    Zeria Pharmaceutical Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//functional-non-ulcer-dyspepsia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//functional-non-ulcer-dyspepsia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//functional-non-ulcer-dyspepsia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments